In this video on OncoDaily, Dr. Amalya Sargsyan sits down with Dr. Eileen O’Reilly , Medical Oncologist at Memorial Sloan Kettering Cancer Center and lead author of the RESOLUTE-302 trial, one of the most significant pancreaticcancer studies presented at the 2026 ASCO Annual Meeting.
Dr. O’Reilly discusses the groundbreaking RESOLUTE-302 Phase III trial evaluating daraxonrasib, a novel pan-RAS inhibitor, in previously treated metastatic pancreatic cancer. The conversation explores how targeting KRAS mutations is transforming a disease long considered one of the most challenging in oncology, delivering significant improvements in overall survival, progression-free survival, response rates, and quality of life.
The discussion also covers the biology of KRAS-driven pancreatic cancer, toxicity management, future combination strategies, the role of genomic profiling, and what the next five years may hold for patients with pancreatic cancer as RAS-targeted therapies move into earlier treatment settings.